TGF-B compositions and method
US5147854A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | May 22, 1990 |
| Grant date | Sep 15, 1992 |
| Priority date | — |
| Expiry date | May 22, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Transforming growth factor-beta (TGF-beta) is enhanced in its therapeutic activity by utilizing it in combination with a synergistic effective amount of a polyunsaturated fatty acid (PUFA). In a preferred embodiment, type 1 transforming growth factor beta (TGF-.sym.1) exhibits enhanced anti-neoplastic activity when utilized in combination with an n=3 or n=6 polyunsaturated fatty acid. Examples of suitable unsaturated fatty acids include linoleic, alpha-linolenic, arachidonic, gamma-linolenic, dihomogammalinolenic, eicosapentaenoic and docosahexaenoic. Combinations of these agents effectively kill various human carcinoma and melanoma cell lines under defined conditions in vitro at picomolar concentrations of TGF-.beta.1 and at .mu.g/ml concentrations of the polyunsaturated fatty acid, levels where the respective two agents acting alone are ineffective.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.